Merus N.V. (NASDAQ:MRUS - Get Free Report) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $69.20 and last traded at $68.09, with a volume of 404036 shares. The stock had previously closed at $67.28.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on MRUS. Alliance Global Partners started coverage on Merus in a research report on Monday. They issued a "buy" rating and a $90.00 target price for the company. Industrial Alliance Securities set a $90.00 price objective on Merus in a research report on Monday. Wall Street Zen lowered Merus from a "hold" rating to a "sell" rating in a research report on Sunday, July 20th. BMO Capital Markets set a $110.00 price objective on Merus and gave the company an "outperform" rating in a research report on Friday, May 23rd. Finally, Needham & Company LLC reduced their price objective on Merus from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $88.75.
Read Our Latest Stock Analysis on Merus
Merus Stock Performance
The firm has a 50 day simple moving average of $60.73 and a two-hundred day simple moving average of $50.90. The stock has a market cap of $5.15 billion, a P/E ratio of -12.42 and a beta of 1.09.
Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($1.06). Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%.The firm had revenue of $8.83 million during the quarter, compared to the consensus estimate of $9.77 million. As a group, equities research analysts predict that Merus N.V. will post -3.85 EPS for the current year.
Insider Activity at Merus
In other news, COO Peter B. Silverman sold 25,000 shares of the business's stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $60.00, for a total value of $1,500,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 82,500 shares of company stock valued at $4,586,340. 3.70% of the stock is currently owned by insiders.
Institutional Trading of Merus
Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Merus by 2,153.6% in the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after buying an additional 603 shares in the last quarter. CWM LLC raised its stake in shares of Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company's stock worth $42,000 after buying an additional 601 shares in the last quarter. State of Wyoming acquired a new position in shares of Merus in the 4th quarter worth $48,000. Wells Fargo & Company MN grew its holdings in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 300 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Merus in the 4th quarter worth $60,000. Institutional investors own 96.14% of the company's stock.
About Merus
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
